Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/57001
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Poppitt, S. | - |
dc.contributor.author | Howe, C. | - |
dc.contributor.author | Lithander, F. | - |
dc.contributor.author | Silvers, K. | - |
dc.contributor.author | Lin, R. | - |
dc.contributor.author | Croft, J. | - |
dc.contributor.author | Ratnasabapathy, Y. | - |
dc.contributor.author | Gibson, R. | - |
dc.contributor.author | Anderson, C. | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | Stroke, 2009; 40(11):3485-3492 | - |
dc.identifier.issn | 0039-2499 | - |
dc.identifier.issn | 1524-4628 | - |
dc.identifier.uri | http://hdl.handle.net/2440/57001 | - |
dc.description | © 2009 American Heart Association, Inc. | - |
dc.description.abstract | <h4>Background and purpose</h4>Fish-derived omega-3 fatty acids have long been associated with cardiovascular protection. In this trial, we assessed whether treatment with a guideline-recommended moderate-dose fish oil supplement could improve cardiovascular biomarkers, mood- and health-related quality of life in patients with ischemic stroke.<h4>Methods</h4>Patients with CT-confirmed stroke were randomized to 3 g/day encapsulated fish oil containing approximately 1.2 g total omega-3 (0.7 g docosahexaenoic acid; 0.3 g eicosapentaenoic acid) or placebo oil (combination palm and soy) taken daily over 12 weeks. Serum triglycerides, total cholesterol and associated lipoproteins, selected inflammatory and hemostatic markers, mood, and health-related quality of life were assessed at baseline and follow-up. The primary outcome was change in triglycerides. Compliance was assessed by capsule count and serum phospholipid omega-3 levels (Australian Clinical Trials Registration: ACTRN12605000207617).<h4>Results</h4>One hundred two patients were randomized to fish oil or placebo. Intention-to-treat and per-protocol (>85% compliance) analyses showed no significant effect of fish oil treatment on any lipid, inflammatory, hemostatic, or composite mood parameters measured. Adherence to treatment based on pill count was good (89%) reflected by increased serum docosahexanoic acid (P<0.001) and eicosapentaenoic acid (P=0.0006) in the fish oil group. Analysis of oil composition, however, showed some degradation and potentially adverse oxidation products at the end of the study.<h4>Conclusions</h4>There was no effect of 12 weeks of treatment with moderate-dose fish oil supplements on cardiovascular biomarkers or mood in patients with ischemic stroke. It is possible that insufficient dose, short duration of treatment, and/or oxidation of the fish oils may have influenced these outcomes. | - |
dc.description.statementofresponsibility | Sally D. Poppitt, Colin A. Howe, Fiona E. Lithander, Karen M. Silvers, Ruey-Bin Lin, John Croft, Yogini Ratnasabapathy, Robert A. Gibson, Craig S. Anderson | - |
dc.language.iso | en | - |
dc.publisher | Lippincott Williams & Wilkins | - |
dc.source.uri | http://dx.doi.org/10.1161/strokeaha.109.555136 | - |
dc.subject | DHA | - |
dc.subject | EPA | - |
dc.subject | fish oils | - |
dc.subject | ischemia | - |
dc.subject | omega-3 | - |
dc.subject | stroke | - |
dc.title | Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: A randomized, controlled trial | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1161/STROKEAHA.109.555136 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Gibson, R. [0000-0002-8750-525X] | - |
Appears in Collections: | Aurora harvest 5 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.